Expert review of pharmacoeconomics & outcomes research

Expert Rev Pharmacoecon Outcomes Res · ISSN (e) 1744-8379 · 6 papers in corpus
meta-analysis 2025
doi:10.1080/14737167.2024.2417014 ·PMID:39394931

OBJECTIVES: This study aims to provide a clear understanding of the relative economic evaluation of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing intrauterine device for treatment of heavy men…

other 2023
doi:10.1080/14737167.2023.2152006 ·PMID:36625547

BACKGROUND: Physicians' preferences for attributes of medical treatments for endometriosis-associated pain have not previously been quantified. METHODS: US obstetrician-gynecologists completed an online discrete-choice experiment survey. I…

observational 2021
doi:10.1080/14737167.2021.1936502 ·PMID:34043465

BACKGROUND: Despite the potential serious outcomes associated with endometriosis, few data is available describing the real clinical practice and costs. The aim of this study was to evaluate the characteristics of patients diagnosed with en…

other 2020
doi:10.1080/14737167.2021.1832468 ·PMID:33140977

INTRODUCTION: We evaluated elagolix and leuprolide from the patient's perspective for the treatment of endometriosis-related pain. AREA COVERED: Preference weights from a published discrete choice experiment were used to evaluate preferenc…

rct 2019
doi:10.1080/14737167.2019.1662301 ·PMID:31530044

Objective: Endometriosis impacts health-related quality of life. The objective was to assess the validity and responsiveness of the Health-Related Productivity Questionnaire, version 2 (HRPQ). Methods: Outcome measures (Endometriosis Health…

review 2017
doi:10.1080/14737167.2018.1411803 ·PMID:29186995

KEYWORDS: Endometriosispelvic painmedical therapysurgerylaparoscopylow-value careminimally disruptive medicinetreatment burden